Science China Life Sciences

, Volume 55, Issue 12, pp 1064–1074 | Cite as

L-theanine inhibits nicotine-induced dependence via regulation of the nicotine acetylcholine receptor-dopamine reward pathway

  • XiaoJing Di
  • JingQi Yan
  • Yan Zhao
  • YanZhong Chang
  • BaoLu Zhao
Open Access
Research Paper


In this study, the inhibitory effect of L-theanine, an amino acid derivative of tea, on the rewarding effects of nicotine and its underlying mechanisms of action were studied. We found that L-theanine inhibited the rewarding effects of nicotine in a conditioned place preference (CPP) model of the mouse and reduced the excitatory status induced by nicotine in SH-SY5Y cells to the same extent as the nicotine receptor inhibitor dihydro-beta-erythroidine (DHβE). Further studies using high performance liquid chromatography, western blotting and immunofluorescence staining analyses showed that L-theanine significantly inhibited nicotine-induced tyrosine hydroxylase (TH) expression and dopamine production in the midbrain of mice. L-theanine treatment also reduced the upregulation of the α4, β2 and α7 nicotine acetylcholine receptor (nAChR) subunits induced by nicotine in mouse brain regions that related to the dopamine reward pathway, thus decreasing the number of cells that could react to nicotine. In addition, L-theanine treatment inhibited nicotine-induced c-Fos expression in the reward circuit related areas of the mouse brain. Knockdown of c-Fos by siRNA inhibited the excitatory status of cells but not the upregulation of TH induced by nicotine in SH-SY5Y cells. Overall, the present study showed that L-theanine reduced the nicotine-induced reward effects via inhibition of the nAChR-dopamine reward pathway. These results may offer new therapeutic strategies for treatment of tobacco addiction.


nicotine addiction L-theanine nicotine acetylcholine receptor (nAChR) dopamine conditioned place preference (CPP) 


  1. 1.
    Gu D F, Kelly T N, Wu X, et al. Mortality attributable to smoking in China. N Engl J Med, 2009, 360: 150–159PubMedCrossRefGoogle Scholar
  2. 2.
    McLellan A T, Lewis D C, O’Brien C P, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA, 2000, 284: 1689–1695PubMedCrossRefGoogle Scholar
  3. 3.
    Mizoue T, Tokui N, Nishisaka K. Prospective study on the relation of cigarette smoking with cancer of the liver and stomach in an endemic region. Intern J Epidem, 2000, 29: 232–237CrossRefGoogle Scholar
  4. 4.
    Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med, 2006, 166: 1571–1577PubMedCrossRefGoogle Scholar
  5. 5.
    Ray R, Schnoll R A, Lerman C. Nicotine dependence: biology, behavior, and treatment. Annu Rev Med, 2009, 60: 247–260PubMedCrossRefGoogle Scholar
  6. 6.
    Rigotti A N. Treatment on tobacco use and dependence. N Engl J Med, 2002, 346: 506–512PubMedCrossRefGoogle Scholar
  7. 7.
    Moxham J. Nicotine addiction. BMJ, 2000, 7232: 391–392CrossRefGoogle Scholar
  8. 8.
    Picciotto M R, Zoli M, Rimondini R. Acetyl-choline receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature, 1998, 6663: 173–177Google Scholar
  9. 9.
    Tapper A R, McKinney S L, Nashmi R. Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science, 2004, 306: 1029–1032PubMedCrossRefGoogle Scholar
  10. 10.
    Bencherif M, Fowler K, Lukas R J. Mechanisms of up-regulation of neuronal nicotinic acetylcholine receptors in clonal cell lines and primary cultures of fetal rat brain. J Pharmacol Exp Ther, 1995, 275: 987–999PubMedGoogle Scholar
  11. 11.
    Peng X, Gerzanich V, Anand R. Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover. Mol Pharmacol, 1994, 46: 523–530PubMedGoogle Scholar
  12. 12.
    Breese C R, Marks M J, Logel J. Effect of smoking history on 3H nicotine binding in human postmortem brain. J Pharmacol Exp Ther, 1997, 282: 7–13PubMedGoogle Scholar
  13. 13.
    Besson M, Granon S, Mameli-Engvall M. Long-term effects of chronic nicotine exposure on brain nicotinic receptors. Proc Natl Acad Sci USA, 2007, 104: 8155–8160PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Nestler E J. Molecuhr mechanisms of drug addiction. Neu ropharm, 2004, 47: 24–32Google Scholar
  15. 15.
    Eschenauer G, Sweet B V. Pharmacology and therapeutic uses of theanine. Am J Health-Syst Ph, 2006, 63: 26–30CrossRefGoogle Scholar
  16. 16.
    Yan J Q, Di X J, Liu C Y, et al. Cessation effect of tea filter on cigarette smoking addiction. Sci China Life Sci, 2010, 53: 533–541PubMedCrossRefGoogle Scholar
  17. 17.
    Nguyen H N, Rasmussen B A, Perry D C. Subtypeselective up-regulation by chronic nicotine of high-affinity nicotinic receptors in rat brain demonstrated by receptor autoradiography. J Pharmacol Exp Ther, 2003, 307: 1090–1097PubMedCrossRefGoogle Scholar
  18. 18.
    Huang E Y, Liu T C, Tao P L. Co-administration of dextromethorphan with morphine attenuates morphine rewarding effect and related dopamine releases at the nucleus accumbens. NaunynSchmiedebergs Arch Pharmacol, 2003, 368: 386–392CrossRefGoogle Scholar
  19. 19.
    Laviolette S R, Nader K, Kooy D V. Motivational state determines the functional role of the mesolimbic dopamine system in the mediation of opiate reward processes. Behav Brain Res, 2002, 129: 17–29PubMedCrossRefGoogle Scholar
  20. 20.
    Jiang H, Luan Z, Wang J, et al. Neuroprotective effects of iron chelator desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload. Neurochem Int, 2006, 49: 605–609PubMedCrossRefGoogle Scholar
  21. 21.
    Shachar B D, Youdim M B. Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson’s disease may depend on iron±melanin interaction. J Neural Transm Suppl, 1990, 29: 251–255Google Scholar
  22. 22.
    Bezard E, Dovero S, Bioulac B, et al. Kinetics of nigral degeneration in a chronic model of MPTP-treated mice. Neurosci Lett, 199, 234: 43–45Google Scholar
  23. 23.
    Gross C E, Ravenscroft P, Dovero S, et al. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. J Neurochem, 2003, 84: 1246–1251PubMedCrossRefGoogle Scholar
  24. 24.
    Miller R G. Simultaneous Statistical Inference. New York: Springer, 1981. 230CrossRefGoogle Scholar
  25. 25.
    Mansvelder H D, Keath J R, McGehee D S. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron, 2002, 33: 905–919PubMedCrossRefGoogle Scholar
  26. 26.
    Panagis G, Nisell M, Nomikos G G. Nicotine injections into the Ventral tegmental area increase locomotion and Fos-like immunoreactivity in the nucleus ac-cumbens of the rat. Brain Res, 1996, 730: 133–142PubMedCrossRefGoogle Scholar
  27. 27.
    Rahman S, Zhang J, Corrigall W A. Effects of acute and chronic nicotine on somatodendritic dopamine release of the rat ventral tegmental area: in vivo microdialysis. Neurosci Lett, 2003, 348: 61–64PubMedCrossRefGoogle Scholar
  28. 28.
    Ferrafi R, Le Novere N, Picciotto M R. Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. Eur J Neurosci, 2002, 15: 1810–1818CrossRefGoogle Scholar
  29. 29.
    Corrigall W A, Coen K M, Adamson K L. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res, 1994, 653: 278–284PubMedCrossRefGoogle Scholar
  30. 30.
    Markou A, Paterson N E. The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tob Res, 2001, 3: 361–373PubMedCrossRefGoogle Scholar
  31. 31.
    Lapchak P A, Araujo D M, Quirion R. Effect of chronic nicotine treatment on nicotinic autoreceptor function and N-[3H] methylcar-bamylcholine binding sites in the rat brain. J Neurochem, 1989, 52: 483–491PubMedCrossRefGoogle Scholar
  32. 32.
    Lapin E P, Maker H S, Sershen H. Action of nicotine on accumbens dopamine and attenuation with repeated administration. Eur J Pharmacol, 1989, 160: 53–59PubMedCrossRefGoogle Scholar
  33. 33.
    Marks M J, Burch J B, Collins A C. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther, 1983, 226: 817–825PubMedGoogle Scholar
  34. 34.
    Sharp B M, Beyer H S, Levine A S. Attenuation of the plasma prolactin response to restraint stress after acute and chronic administration of nicotine to rats. J Pharmacol Exp Ther, 1987, 241: 438–442PubMedGoogle Scholar
  35. 35.
    Shram M J, Funk D, Li Z. Acute nicotine enhances c-FOS mRNA expression differentially in reward-related substrates of adolescent and adult rat brain. Neuro Sci, 2007, 418: 286–291Google Scholar
  36. 36.
    Salminen O, Seppa T, Gaddnas H. The effects of acute nicotine on the metabolism Of dopamine and the expression of Fos protein in striatal and limbic brain areas of rats during Chronic nicotine infusion and its withdrawal. J Neuro Sci, 1999, 19: 8145–8151Google Scholar
  37. 37.
    Marks M J, Grady S R, Yang J M. Desensitization of nicotine-stimulated 86Rb+ efflux from mouse brain synaptosomes. J Neurochem, 1994, 63: 2125–2135PubMedCrossRefGoogle Scholar
  38. 38.
    Schwartz R D. Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo. Science, 1983, 220: 214–216PubMedCrossRefGoogle Scholar
  39. 39.
    Benwell M E M, Balfour D J K. The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharmacol, 1992, 105: 849–856PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Balbani A P S, Montovani J C. Methods for smoking cessation and treatment of nicotine dependence. Rev Bras Otorrinolaringol, 2005, 71: 820–826CrossRefGoogle Scholar
  41. 41.
    Ray R, Schnoll R A, Lerman C. Nicotine dependence: biology, behavior, and treatment. Annu Rev Med, 2009, 60: 247–260PubMedCrossRefGoogle Scholar
  42. 42.
    Rigotti A N. Treatment on tobacco use and dependence. N Engl J Med, 2002, 346: 506–512PubMedCrossRefGoogle Scholar
  43. 43.
    Peng R L, Wang S L. Nicotine sublingual tablet for smoking cessation in 115 cases: a double-blind randomized placebo-controlled clinical trial. J Clin Rehabilit Tissue Engin Res, 2007, 11: 10443–10446Google Scholar
  44. 44.
    Liu Q, Tao Y, Zhao B L. ESR study on scavenging effect of nicotine on free radicals. Appl Mag Reson, 2003, 24: 105–112CrossRefGoogle Scholar
  45. 45.
    Liu Q, Zhao B L. Nicotine attenuates β-amyloid peptide induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures. Brit J Pharmoco, 2004, 1141: 746–754CrossRefGoogle Scholar
  46. 46.
    Xie Y X, Bezard E, Zhao B L. Unraveling the receptor-independent neuroprotective mechanism in mitochondria. J Biol Chem, 2005, 396: 84–92Google Scholar
  47. 47.
    Zhang J, Liu Q, Liu N Q, et al. Nicotine reduces β-amyloidosis by regulating metal homeostasis. FASEB J, 2006, 20: 1212–1214PubMedCrossRefGoogle Scholar
  48. 48.
    Liu Q, Zhang J, Qin C, et al. Dissecting the signalling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. FASEB J, 2007, 21: 61–73PubMedCrossRefGoogle Scholar
  49. 49.
    Zhao B L. The molecular mechanism of treatment of Alzheimer’s disease and Parkinson’s disease by nicotine. Acta Biophys China, 2007, 23: 81–92Google Scholar
  50. 50.
    Di X, Yan J, Zha Y, et al. L-theanine protects the APP (Swedish mutation) transgenic SH-SY5Y cell against glutamate-induced excitotoxicity via inhibition of the NMDA receptor pathway. Neuroscience, 2010, 168: 778–786PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2012

Authors and Affiliations

  • XiaoJing Di
    • 1
  • JingQi Yan
    • 1
  • Yan Zhao
    • 2
  • YanZhong Chang
    • 3
  • BaoLu Zhao
    • 1
  1. 1.State Key Laboratory of Brain and Cognitive Science, Institute of BiophysicsChinese Academy of SciencesBeijingChina
  2. 2.Department of Food Sciences and TechnologyHarbin Institute of Technology at WeihaiWeihaiChina
  3. 3.Institute of Molecular NeurobiologyHebei Normal UniversityShijiazhuangChina

Personalised recommendations